These findings support the potential benefit of targeting ERK5 in the macrophage compartment of the tumor stroma and underscore the utility of using the GEMMs for preclinical testing of the potential therapies targeting the tumor microenvironment. This evidence concerns the gene MAPK7 and neoplasm.